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Background: Patients with atrial fibrillation (AF) frequently also have CAD or other indications for aspirin. We aim to define the efficacy and safety 
of apixaban in patients with AF who are taking and not taking aspirin.
Methods: ARISTOTLE included 18,201 patients randomized to apixaban 5 mg twice daily or warfarin. The use of concomitant aspirin (≤165 mg 
daily) was left to the discretion of the treating physician. We compared baseline characteristics and the efficacy and safety of apixaban compared 
with warfarin among patients taking and not taking aspirin at baseline.
Results: At baseline, 5632 (31%) patients were taking aspirin. Patients taking aspirin were more likely to have CAD (50% vs 31%), PAD (6% vs 4%), 
diabetes (28% vs 24%), and paroxysmal AF (17% vs 14%), equally likely to have prior stroke (12% vs 12%) and less likely to have used a VKA prior to 
randomization (39% vs 65%) or have AF of >2 year duration (45% vs 56%) compared with patients not taking aspirin. Outcomes by baseline aspirin 
use are shown in the table.
Conclusions: Use of concomitant aspirin therapy in patients with AF is common, particularly in patients with CAD, and tends to be associated with 
worse outcomes and increased bleeding. The significant reductions in stroke or systemic embolism and major bleeding with apixaban compared 
with warfarin are similar regardless of baseline aspirin use. Ongoing analyses will address switching off and on aspirin and other antiplatelet agents 
during the trial. 
Endpoint Aspirin No Aspirin Interactionp-value
Apixaban Warfarin HR (95% CI) Apixaban Warfarin HR (95% CI)
Rate/yr (n) Rate/yr (n)
Apixaban vs 
Warfarin
Rate/yr (n) Rate/yr (n)
Apixaban vs 
Warfarin
Stroke or Systemic Embolism 1.34 (70) 1.86 (94) 0.72(0.53 - 0.98) 1.23(142) 1.48(171) 0.83(0.67 - 1.04) 0.46
Ischemic Stroke or Systemic 
Embolism
1.09 (57) 1.28(65) 0.85(0.60 - 1.21) 1.02(118) 1.08(125) 0.946(0.74 - 1.21) 0.63
Myocardial Infarction 0.80(42) 0.77(39) 1.046(0.68 - 1.62) 0.41(48) 0.54(63) 0.76(0.52 - 1.11) 0.28
All Cause Death 4.02(216) 4.69(244) 0.86(0.71 - 1.03) 3.29(387) 3.61(425) 0.91(0.80 - 1.05) 0.60
Major Bleeding 2.73(129) 3.68(164) 0.75 (0.59 - 0.94) 1.87(198) 2.84(298) 0.66(0.55 - 0.79) 0.42
Major or Clinically Relevant Non-
Major Bleeding
4.93(228) 6.86(298) 0.72 (0.61 - 0.86) 3.69(385) 5.65(579) 0.65(0.58 - 0.74) 0.38
Any Bleeding 21.10(826) 30.34(1030) 0.72 (0.65 - 0.79) 16.79(1530) 24.01(2030) 0.71(0.67 - 0.76) 0.96
Intracranial Hemorrhage
0.37
(18)
1.06(48) 0.36 (0.21 - 0.61) 0.32(34) 0.70(74) 0.46(0.30 - 0.69) 0.47
